Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
NEW YORK, July 26, 2024 - Psyence Group Inc (Psyence Group) (CSE: PSYG), a life science biotechnology company specializing in the use of nature-derived psilocybin for mental health and wellbeing, is excited to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (PBM or Psyence Biomed), has recently exported nature-derived psilocybin to Australia and shared an update on their upcoming Phase IIb clinical trial.
Psilocybin, a naturally occurring psychedelic compound found in certain species of mushrooms, has shown great potential in treating various mental health disorders. Psyence Group, in collaboration with its associate Psyence Biomed, has been at the forefront of exploring the therapeutic benefits of psilocybin.
The export of nature-derived psilocybin to Australia signifies a significant milestone for Psyence Biomed as it expands its global reach and provides access to innovative mental health treatments to a wider population. Australia has seen a growing interest in psychedelic-assisted therapy, and this export will cater to the increasing demand in the country.
Additionally, Psyence Biomed has shared an update on its upcoming Phase IIb clinical trial. This trial aims to further evaluate the efficacy and safety of nature-derived psilocybin in a larger patient population. Phase IIb trials are crucial in gathering more data and insights before moving towards regulatory approval and commercialization of the therapy.
The progress made by Psyence Biomed in exporting psilocybin to Australia and advancing its clinical trials showcases the significant potential of psilocybin in revolutionizing mental healthcare. As more research and clinical trials are conducted, the medical community is hopeful about the positive outcomes that nature-derived psilocybin could bring for patients suffering from mental health disorders.
Comments